Cibus director Gerhard Prante sells $2,909 in stock

Published 14/02/2025, 22:30
Cibus director Gerhard Prante sells $2,909 in stock

SAN DIEGO—Cibus, Inc. (NASDAQ:CBUS) director Gerhard Prante recently executed a stock sale, according to a filing with the Securities and Exchange Commission. The transaction comes as the company's stock, currently valued at $87.82 million in market capitalization, has experienced significant volatility, declining nearly 86% over the past year. According to InvestingPro analysis, the stock is currently trading below its Fair Value. On February 13, Prante sold 1,150 shares of Cibus Class A common stock at a price of $2.53 per share, totaling $2,909. Following this transaction, Prante retains ownership of 16,907 shares.

This sale was conducted automatically under a Rule 10b5-1 trading plan that Prante adopted on August 16, 2024. Such plans allow insiders of publicly traded corporations to set up a predetermined schedule for buying or selling stocks, thereby helping to avoid concerns over insider trading.

In other recent news, Cibus has been the subject of several significant developments. Canaccord Genuity analysts have revised their outlook on Cibus, lowering the stock's price target from $20.00 to $18.00, while maintaining a Buy rating. This adjustment follows Cibus's announcement of a direct stock offering aimed at funding ongoing projects, with an expected generation of approximately $22.6 million.

In addition to financial adjustments, Cibus has also made changes to its executive compensation, setting a new base salary of $320,000 for executive Carlo Broos. The change was approved by the Compensation Committee of Cibus's Board of Directors and is documented in a recent filing with the Securities and Exchange Commission.

Moreover, Jefferies has lowered its price target for Cibus to $5.00 from the previous $8.00, while maintaining a Hold rating. This adjustment is due to Cibus's focus on maintaining the quality of its royalty economics and the company's potential to enhance its negotiating stance if the European Union approves gene editing. These are recent developments that reflect the ongoing dynamics within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.